Dato' Mohammed Azlan bin Hashim was appointed to the Board of IHH Healthcare Berhad ("IHH") in 2011 as Deputy Chairman and was re-designated from Non-Independent Non-Executive Deputy Chairman to Non-Independent Non-Executive Chairman on 1 January 2018. On 27 November 2018, Dato' Mohammed Azlan bin Hashim was re-designated from Non-Independent Non-Executive Chairman to Independent Non-Executive Chairman following his cessation as a nominee director of Khazanah Nasional Berhad.
Dato' Azlan previously served as Executive Chairman of the (then) Kuala Lumpur Stock Exchange Group from 1998 to 2004 and in various other senior management roles, including at Bumiputra Merchant Bankers Berhad and Amanah Capital Malaysia Berhad.
Dr Tan See Leng was appointed the Managing Director and Chief Executive Officer of IHH Healthcare Berhad ("IHH") in January 2014 after serving as an Executive Director on the IHH Board for two years. Dr Tan is also the Group CEO and Managing Director of Parkway Pantai Limited, a position he assumed in 2011. He also serves on the Boards of IHH subsidiaries, namely Parkway Pantai Limited, Fortis Healthcare Limited, SRL Limited and Acibadem Saglik Yatirimlari Holding A.S. ("ASYH") Group and on a Board Committee of ASYH. He also serves on the Advisory Board of Lee Kong Chian School of Business at Singapore Management University and on the Board of Parkway Trust Management Limited ("PTM"), an indirect wholly-owned subsidiary of IHH. PTM manages Parkway Life Real Estate Investment Trust, which is listed on the Singapore Exchange Securities Trading Limited.
Prior to this, Dr Tan was the CEO of Parkway Holdings Limited from April 2010, a position he rose to fairly quickly after he joined Parkway in 2004 as Chief Operating Officer of Mount Elizabeth Hospital. As a young entrepreneur, Dr Tan founded a private primary healthcare group at the age of 27 and subsequently developed it into the second largest primary healthcare group in Singapore before successfully selling the company to a leading global health-plan and insurance provider.
With over 27 years of healthcare experience, Dr Tan has served as an active member of various medical committees, such as Singapore Ministry of Health's MediShield Life Review Committee. He has been re-appointed Adjunct Assistant Professor of Duke-NUS Graduate Medical School Singapore, Office of Education, for the period until 2019.
Dr Kelvin Loh Chi-Keon was appointed the Chief Executive Officer ("CEO") (designate) and Executive Director of IHH Healthcare Berhad ("IHH") on 1 July 2019 and will assume the position of Managing Director and CEO of IHH Healthcare with effect from 1 January 2020.
Dr Loh started his career as a practising physician after a decade in the public sector in areas such as clinical services development, hospital planning and hospital operations. Dr Loh first joined the IHH Group in 2008. Between 2008 and 2017, he held a number of senior management roles, before taking over as CEO for its Singapore Operations Division, covering among other services, the 4 multi-specialty tertiary hospitals - Mount Elizabeth Orchard, Mount Elizabeth Novena, Gleneagles and Parkway East.
In 2017, Dr Loh moved to Columbia Asia Group as CEO where he was responsible for overseeing Columbia Asia Group's 28 hospitals across 4 countries in Asia, before he rejoined IHH.
With more than 20 years' experience in the healthcare industry and a strong track record of delivery, Dr Loh is a senior healthcare executive with extensive experience in leading large healthcare businesses, building relationships with stakeholders, managing hospital operations, financial management and developing talent.
An expert in lean management systems, Dr Loh was previously a member of Singapore's National Expert Advisory Panel for Healthcare Productivity and Advisor to the Asia Productivity Organisation. Dr Loh was also a Visiting Lecturer for the Master of Public Health and Master of Business Administration programmes at the National University of Singapore.
Dr Loh holds a Medical Degree and a Master of Business Administration from the National University of Singapore.
Appointed to the Board of IHH Healthcare Berhad ("IHH") in 2012, Mr Mehmet Ali Aydinlar is also the Chairman of Acibadem Saglik Yatirimlari Holding A.S. ("ASYH"), a 90%-owned subsidiary of IHH. He was re-designated from Executive Director to Non-Executive Director of IHH on 1 March 2019 following his cessation as the Chief Executive Officer ("CEO") of ASYH. Mr Mehmet Ali Aydinlar, after an illustrious tenure as founding CEO of ASYH, continues to serve as the Chairman of the Board of the Acibadem group of companies, which includes A Plus, Acibadem Project Management, Acibadem Mobile Services and Acibadem Labmed. He is also the Chairman of the Turkish Accredited Hospitals Association and Vice Chairman of Private Hospitals and Healthcare Institutions Association (OHSAD).
As of 2015, Mr Aydinlar has been serving on the board of the Foreign Economic Relations Board (DEIK). This institution is responsible for leading foreign economic relations within the Turkish private sector in a myriad of sectors, as well as for increasing the export volume of Turkish businesses and coordinating similar business development activities.
A certified public accountant-turned-entrepreneur, Mr Aydinlar has been recognised for his extensive experience in management and involvement in the healthcare sector since 1993. Mr Aydinlar was chosen "Ernst & Young Entrepreneur of the Year, Turkey" for the year 2018 and in 2015, Mr Aydinlar received the "Lifetime Achievement Award" from Bogazici University, one of the most prestigious higher education institutions in Turkey. Prior to this, he was elected "Business Man of the Year" by the same university. Mr Aydinlar was also awarded "The Eminent Services Award of the Grand National Assembly of Turkey" in 2010. He was also chosen to be "The Person with Most Contribution to Development of Healthcare" by the Turkish Healthcare Volunteers Organisation. In 2006, he was named "Male Entrepreneur of the Year" in a survey conducted by Ekonomist Magazine and "Business Executive of the Year" by Dunya Newspaper and Istanbul University's School of Business Administration.
Being a philanthropist, Mr Aydinlar is also the Chairman of the Board of Trustees of Acibadem University, an ambitious social responsibility undertaking initiated by Mr Aydinlar to advance healthcare in Turkey through education and research. For two years in a row, Mr Aydinlar was recognised by Capital Magazine for his philanthropic efforts as one of the top business people with the most charitable donations, ranking at number five in 2014.
Appointed to the Board of IHH Healthcare Berhad ("IHH") in 2016, Mr Chintamani Bhagat is the Executive Director in charge of Khazanah Nasional Berhad's holding in IHH and other investments in the healthcare sector, and is concurrently the head of private markets for South Asia. He also serves on the Boards of IHH subsidiaries, namely Fortis Healthcare Limited and Acibadem Saglik Yatirimlari Holding A.S. ("ASYH") Group and Board Committees of ASYH.
Prior to joining Khazanah, Mr Bhagat spent 14 years at McKinsey & Company in Singapore, including six years as Managing Partner for the Singapore office. He was a leader in healthcare practice, serving hospital systems across Asia, as well as a leader in Principal Investor practice, serving several sovereign wealth funds, private equity firms and family owned businesses. He also founded and led McKinsey's corporate governance service line. Preceding his time at McKinsey, Mr Bhagat was the Chief Executive Officer of an engineering and construction firm in India.
Appointed to the Board of IHH Healthcare Berhad ("IHH") on 1 April 2017, Mr Koji Nagatomi currently serves as the Managing Officer and Chief Operating Officer, Healthcare and Service Business Unit of Mitsui & Co., Ltd ("Mitsui") at its Tokyo Headquarters. Between 2011 and 2015, he served in the position of General Manager for several of Mitsui's divisions. These included Mitsui's Planning and Administrative Division (Machinery and Infrastructure), First Projects Development Division and Corporate Communications Division. In May 2008, he was appointed Deputy General Manager of Toyo Engineering Corporation's Corporate Planning Unit.
Preceding his tenure at Toyo Engineering Corporation, Mr Nagatomi served as the General Manager of the Infrastructure Project Development Division of Mitsui & Co. (Asia Pacific) Pte Ltd in Kuala Lumpur from December 2003. Prior to that, Mr Nagatomi joined the Project Development Division of Mitsui's Indonesia Project Section which was based out of Tokyo. He spent eight years at Mitsui & Co. (USA), Inc in Houston under the Plant & Energy Project Development Department after beginning his professional career in 1986 in Mitsui's Chemical Plant Division.
Appointed to the Board of IHH Healthcare Berhad ("IHH") in 2012, Ms Rossana Annizah binti Ahmad Rashid also serves on the Board and Board Committee of Acibadem Saglik Yatirimlari Holding A.S., an indirect subsidiary of IHH. She is also a Non-Executive Director of Parkway Trust Management Limited ("PTM"), an indirect wholly-owned subsidiary of IHH. PTM manages Parkway Life Real Estate Investment Trust which is listed on the Singapore Exchange Securities Trading Limited.
Ms Rossana concurrently serves as a member of the Investment Panel and the Investment Panel Risk Committee of Malaysia's Employees Provident Fund. She also serves as the Country Chairman of the Jardine Matheson Group of Companies in Malaysia and Deputy Chairman/Non-Independent Non-Executive Director on the Board of Cycle & Carriage Bintang Berhad, a member of the Jardine Matheson Group. She was appointed as Independent Non-Executive Director of edotco Group Sdn Bhd in May 2016 and Independent Non-Executive Director of Celcom Axiata Berhad in May 2017, both are subsidiaries of Axiata Group Berhad.
Prior to her current roles, Ms Rossana was a career professional holding leadership positions in the telecommunications and banking sectors. She previously served in various senior management roles with TIME dotCom Berhad, Maxis Berhad and RHB Bank Berhad, after beginning her banking career with Citibank Malaysia. With a combined 30 years of experience, Ms Rossana has broad experience in business strategy, identifying sustainable monetisation models, understanding customers and competition, as well as the need for reviewing monetisation models by focusing on both revenue management and cost management.
Appointed to the Board of IHH Healthcare Berhad ("IHH") in 2014, Mr Shirish Moreshwar Apte is currently also the Independent, Non-Executive, Chairman of Pierfront Mezzanine Fund Pte Ltd. He also serves on the Boards of IHH subsidiaries, namely Fortis Healthcare Limited and Acibadem Saglik Yatirimlari Holding A.S. ("ASYH") and on a Board Committee of ASYH. He concurrently serves on several Boards of Directors, including the Commonwealth Bank of Australia, the Supervisory Board of Bank Handlowy, Poland and Fullerton India Credit Company Limited.
He was a Council Member of the Institute of Banking and Finance Singapore until his retirement in May 2018. Prior to his retirement from Citigroup in 2014 as Chairman of Asia Pacific Banking, Mr Apte had built up an impressively extensive 32-year career with Citibank/Citigroup. He held numerous positions with Citibank/Citigroup serving in Singapore (2011–2013), Hong Kong (2009–2011), London (2003–2009), Poland (1997–2003) and London (1993–1997). He also supervised operations in the emerging markets covering Central and Eastern Europe, Middle East, Africa ("CEEMEA") and Asia Pacific. He was appointed head of Citi's Corporate and Investment bank in India, CEO for Citibank Poland and regional CEO, first for CEEMEA and then Asia Pacific. Mr Apte was also a member of Citigroup's Executive and Operating Committees from 2008–2012 and the Group's Business Practices Committee. He began his career in the banking division of Citibank India in 1981.
Appointed to the Board of IHH Healthcare Berhad ("IHH") in 2018, Ms Jill Margaret Watts currently serves on the Board of Governors of Sidra Medicine. She was previously a Director of the Australian Chamber of Commerce, United Kingdom, the Royal Australian Flying Doctor Service, United Kingdom, Ramsay Sante in France and the Netcare Group in South Africa. Ms Watts also served on several Industry Boards including NHS Partners Network and the Association of Independent Hospital Operators.
Ms Watts was the Group Chief Executive Officer of BMI (GHG) Health Care Group ("BMI Healthcare") in United Kingdom from 2014 to 2017. She has over 40 years of experience in the healthcare industry and has held a number of senior executive roles in Australia and the United Kingdom. Prior to her appointment at BMI Healthcare, she was the Group Chief Executive Officer of Ramsay Health Care, United Kingdom ("Ramsay UK") for over six years. She was the Chair of NHS Partners Network between 2009 and 2012, where she was actively engaged in influencing governments on the benefits of having a strong and vibrant private healthcare sector.
In 2010, Ms Watts was voted as the most influential leader in United Kingdom private healthcare and in 2013 as one of healthcare's most inspirational women. Under her leadership, Ramsay UK was voted as the best United Kingdom private hospital provider in 2009 and 2013.
Ms Quek Pei Lynn is an alternate director to Mr Chintamani Aniruddha Bhagat on the Board of IHH Healthcare Berhad ("IHH"), a role she assumed on 23 September 2016. She also serves on the Board and Board Committee of IHH subsidiary, IMU Health Sdn Bhd. Prior to her current position in IHH, she was appointed alternate director to YM Tengku Dato' Sri Azmil Zahruddin bin Raja Abdul Aziz on 25 October 2012 and ceased to be his alternate on 23 September 2016, following his resignation as a Director of IHH. Ms Quek also serves as a Director at the Investments Division of Khazanah Nasional Berhad ("Khazanah"), a position she has held since joining the company in 2007.
Prior to joining Khazanah, Ms Quek served in the Corporate Finance Division at AmInvestment Bank Berhad for nine years from 1997 to 2006 after beginning her career as an auditor with PriceWaterhouse Coopers in 1994.
Appointed to the Board of IHH Healthcare Berhad ("IHH") in 2019, Mr Takeshi Saito was an alternate director to Mr Koji Nagatomi, a role he assumed since April 2017. He was also an alternate director to Mr Satoshi Tanaka, a former Director of IHH, from June 2015 to April 2016. He also serves on certain Boards of IHH subsidiaries under Acibadem Saglik Yatirimlari Holding A.S. Group. Mr Saito currently serves as Chief Executive Officer ("CEO") of MBK Healthcare Management ("MHM"), a wholly-owned subsidiary of Mitsui & Co., Ltd ("Mitsui") based in Singapore, which manage the healthcare assets within the portfolio of Mitsui.
Mr Saito has spent most of his career in the healthcare industry. Preceding his appointment as CEO of MHM, he served as General Manager of Healthcare Business 1st Department in Healthcare Business Division of Mitsui. In 2017, he was an Executive Assistant to a Representative Director and Executive Vice President of Mitsui. Between 2015 and 2016, he was the General Manager of the Provider Network Department, Medical Healthcare Business Division 1, Consumer Service Business Unit of Mitsui and during that time, he also sat on the Board and Executive Committee of Parkway Pantai Limited as an alternate director. In 2011, Mr Saito was seconded to Parkway Group Healthcare as Vice President of Strategic Planning, following his appointment as Director of the Medical Healthcare Business Department at Mitsui, where he led the investment in IHH.
Prior to this in 2007, Mr Saito was appointed Manager of the Strategic Planning/Business Development Department of the Life Science Division at Mitsui, which subsequently became the Medical Healthcare Division in 2008. He also initiated the 10-year plan for the newly formed Medical Healthcare Division.
Mr Tomo Nagahiro is an alternate director to Mr Koji Nagatomi on the Board of IHH Healthcare Berhad ("IHH"), a role he assumed on 3 April 2019. Since April 2019, he has been General Manager of Healthcare Business 1st Department in Healthcare Business Division of Mitsui & Co., Ltd ("Mitsui"), overseeing Mitsui's investment in IHH.
Mr Nagahiro has over 20 years of working experience having served in multiple divisions in Mitsui, spanning from strategic planning, business development and operations management. Preceding his appointment as General Manager of Healthcare Business 1st Department at Mitsui, he was seconded to MIMS Pte. Ltd. ("MIMS") which is based in Singapore as the Chief Operating Officer from 2015 to 2018. MIMS is one of the largest multichannel providers of drug information and medical education for healthcare professionals in Asia Pacific region. During this period, he was responsible for the general management of regional business activities and development of the company.
Prior to this, Mr Nagahiro was seconded to Parkway Pantai Limited, a wholly-owned subsidiary of IHH, as Assistant Vice President of Strategic Planning and Business Development where he led multiple business development projects from 2013 to 2015.